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ABSTRACT
Aims/Introduction: Canagliflozin is a sodium–glucose cotransporter 2 inhibitor under
development for the treatment of type 2 diabetes. Our aim was to examine its efficacy
and safety as monotherapy or in combination with commonly used oral antihyperglyce-
mic drugs in Japanese patients with type 2 diabetes.
Materials and Methods: Patients on diet/exercise alone or diet/exercise plus an oral
antihyperglycemic drug (sulfonylurea, glinide, a-glucosidase inhibitor, biguanide, thiazolid-
inedione or dipeptidyl peptidase-4 inhibitor) were randomized to either 100 or 200 mg
canagliflozin while continuing prior therapy. Patients were treated for 52 weeks in an
open-label manner.
Results: Canagliflozin significantly reduced hemoglobin A1c, fasting plasma glucose and
bodyweight in all the study groups. Improvements were apparent by 4 weeks of treat-
ment, and were maintained for 52 weeks. The reduction in hemoglobin A1c ranged from
-0.80 to -1.06%, and from -0.93 to -1.26% in the 100 and 200 mg canagliflozin groups,
respectively. Drug-related adverse events occurred in approximately one-third of patients,
and included hypoglycemia/asymptomatic hypoglycemia and pollakiuria. Hypoglycemia/
asymptomatic hypoglycemia was most common in patients treated with a sulfonylurea.
Most adverse events were classified as mild or moderate in severity.
Conclusions: The results of the present study confirmed that treatment with canagliflo-
zin resulted in significant reductions in glycemic control and bodyweight that were main-
tained for 52 weeks of treatment irrespective of whether it was administered as
monotherapy or in combination with another oral antihyperglycemic drug. Canagliflozin
was well tolerated, with a low incidence of drug-related adverse events. This trial was
registered with ClinicalTrials.gov (no. NCT01387737).
INTRODUCTION
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a novel
class of drugs under development for the treatment of type 2
diabetes that work by blocking glucose reabsorption in the kid-
ney. Inhibition of SGLT2 and blocking glucose reabsorption
lowers the renal threshold for glucose, which enhances urinary
glucose excretion (UGE) and ultimately lowers PG1–4.
Canagliﬂozin (TA-7284 and JNJ-28431754; Mitsubishi Tana-
be Pharma Corporation/Janssen Research & Development,
LLC, Tokyo, Japan; Raritan, NJ, USA) is a SGLT2 inhibitor
that was recently approved by the United States Food and
Drug Administration for the treatment of type 2 diabetes5.
Studies in Western populations conﬁrmed that canagliﬂozin
signiﬁcantly reduced hemoglobin A1c (HbA1c) when used as
monotherapy (with diet and exercise)6, in combination with
metformin7,8 and in combination with metformin plus a sulfo-
nylurea9.Received 17 March 2014; revised 4 July 2014; accepted 7 July 2014
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CLINICAL TRIAL
In Japanese patients, results of 12-week10 and 24-week11
studies have conﬁrmed that 100 or 200 mg canagliﬂozin sig-
niﬁcantly reduced HbA1c, fasting plasma glucose (FPG) and
2-h plasma glucose after a meal or glucose load compared
with placebo, and reduced bodyweight when used as mono-
therapy.
According to the Japan Diabetes Society’s Treatment Guide
for Diabetes, all classes of antihyperglycemic drugs can be used
as monotherapy in Japan12. However, many patients continue
to have inadequate glycemic control with diet/exercise alone or
with an antihyperglycemic drug as monotherapy. Therefore, it
is essential to consider the effects of adding novel oral agents,
including SGLT2 inhibitors, to ongoing therapies if insulin ther-
apy can be avoided.
Accordingly, the aim of the present study was to determine
the long-term efﬁcacy and safety of canagliﬂozin in Japanese
patients with type 2 diabetes and poor glycemic control (ele-
vated HbA1c) on diet/exercise therapy alone or diet/exercise in
combination with an existing oral antihyperglycemic drug. The
present study was carried out in accordance with the Japanese
Guideline for the Clinical Evaluation of Oral Hypoglycemic
Agents13, which states that the efﬁcacy and safety of oral anti-




Outpatients aged ≥20 years with type 2 diabetes diagnosed
≥3 months before screening and HbA1c (National Glycohe-
moglobin Standardization Program values) of ≥7.0 to ≤10.0%
(monotherapy) or ≥7.0 to ≤10.6% (combination therapy) were
eligible for the present study. Patients were eligible for
monotherapy in this study if their diet/exercise therapy had
continued unchanged and they had not used an antidiabetic
drug for ≥83 days before week 0 (start of the treatment
period). Patients who had used a sulfonylurea (glimepiride,
gliclazide or glibenclamide), a glinide (nateglinide or mitigli-
nide), an a-glucosidase inhibitor (a-GI; voglibose, miglitol or
acarbose), a biguanide (metformin), a thiazolidinedione (piog-
litazone) or a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitag-
liptin, vildagliptin or alogliptin) for ≥83 days before week 0
were eligible for combination therapy in the present study.
Patients who had used another antidiabetic drug were to
enter a washout period of ≥83 days after providing informed
consent and before starting the treatment period. Major
exclusion criteria included contraindications to the study
drugs, history or current serious diabetic complication, FPG
>270 mg/dL on two consecutive visits between providing
informed consent and week 0, indication for insulin, concur-
rent urinary tract/genital infection, triglyceride level ≥600 mg/
dL at screening, systolic/diastolic blood pressure (SBP/DBP)
≥160/≥100 mmHg, history of or current cardiac failure (New
York Heart Association Class III or IV), myocardial infarction
or cerebrovascular disorder <6 months before week 0, serious
liver/kidney disorders, estimated glomerular ﬁltration rate
<50 mL/min/1.73 kg/m2, urinary albumin/creatinine ratio
≥300 mg/g creatinine at screening, and participation in
another clinical trial or receiving treatment with an investiga-
tional product in ≤12 weeks of providing informed consent
or prior treatment with canagliﬂozin.
The study was carried out in accordance with the ethical
principles of the Declaration of Helsinki, the Pharmaceutical
Affairs Law of Japan, Good Clinical Practice and the approved
study protocol. The study was approved by institutional review
boards at each participating site. All patients provided written














































Figure 1 | Study design. Visits were scheduled every 4 weeks during the treatment period.
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Study Design
This was a multicenter, randomized, open-label, 52-week study
(Figure 1). The trial was registered on ClinicalTrials.gov (no.
NCT01387737). After providing informed consent, patients on
diet/exercise alone or using one of six classes of oral antihyper-
glycemic agents underwent screening. A washout period was
also included if another antihyperglycemic agent was used. At
week 0, eligible patients were randomized to 100 or 200 mg
canagliﬂozin. Diet/exercise therapy and the combination antihy-
perglycemic drug were to be continued unchanged from
83 days before week 0 until the end of the follow-up period.
Visits were scheduled every 4 weeks during the treatment
period, and at 2 weeks after study completion or at study with-
drawal (if before week 52).
The combination drugs were to be used in accordance with
their approved dosage and administration. The doses of canagli-
ﬂozin and the combination antihyperglycemic drug were to be
continued unchanged throughout the study, although the dose of
the combination drug could be modiﬁed in the follow-up period
if the FPG level met the criteria for withdrawal (>270 mg/dL).
The doses of sulfonylureas or glinides could be reduced if the
investigator considered there was a risk of hypoglycemia.
Patients were randomized by the study enrolment center to
either 100 or 200 mg canagliﬂozin, and the patients were pre-
scribed the allocated dose by the investigator. Randomization
was carried out using a variable block design. The doses of
canagliﬂozin were chosen after considering the reductions in
HbA1c, FPG and 2-h plasma glucose, and comparable safety
proﬁles of doses of 100–300 mg canagliﬂozin in an earlier Japa-
nese dose-ﬁnding study10.
Continuous systemic corticosteroid treatment for ≥2 weeks,
appetite suppressants and other investigational products were
prohibited during the study. Patients using glibenclamide were
prohibited from using bosentan hydrate.
The investigator verbally assessed compliance with diet/exer-
cise therapy, the combination drug and canagliﬂozin through-
out the study. The investigators were not given speciﬁc
guidelines for encouraging adherence to diet/exercise therapy,
only a guideline that the prior therapy should be continued.
Efﬁcacy Outcomes
The efﬁcacy variables included the changes in HbA1c (and pro-
portion of patients with HbA1c <7.0%), FPG, bodyweight
(absolute and percent change; and proportion of patients with
a decrease in bodyweight of ≥5%), waist circumference, lipids
(absolute and percent changes in triglyceride, high-density lipo-
protein cholesterol [HDL-C], low-density lipoprotein cholesterol
[LDL-C] and non-HDL-C; change in LDL-C/HDL-C ratio),
SBP/DBP, proinsulin/C-peptide ratio and homeostatic model
assessment (HOMA)2-%B. The time-courses of changes in
HbA1c, FPG and bodyweight were also assessed. The efﬁcacy
outcomes were generally measured at each visit during the
study, including at the time of providing informed consent, at
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Figure 2 | Changes in (a) hemoglobin A1c (HbA1c), (b) fasting plasma glucose and (c) bodyweight from baseline to the end of treatment with
last observation carried forward. Light bars, 100 mg canagliflozin; dark bars, 200 mg canagliflozin. Values are means – standard deviation. a-GI,
a-glucosidase inhibitor; DPP-4, dipeptidyl peptidase-4 inhibitor; NGSP, National Glycohemoglobin Standardization Program; SU, sulfonylurea; TZD,
thiazolidinedione.
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All laboratory tests were carried out at SRL Inc. (Tokyo,
Japan). HbA1c was measured in Japan Diabetes Society units
and converted to National Glycohemoglobin Standardization
Program units14 using the certiﬁed formula: HbA1c (NGSP
[%]) = HbA1c (JDS [%]) 9 1.02 + 0.25.
Safety
Adverse events (AEs) and safety assessments, including symp-
toms or signs of hypoglycemia, vital signs, 12-lead electrocardi-
ography and clinical laboratory tests were to be recorded
throughout the study. Hypoglycemia was classiﬁed as hypogly-
cemia (typical hypoglycemic symptoms were present irrespec-
tive of the blood glucose level) and asymptomatic
hypoglycemia (typical hypoglycemic symptoms were absent,
but the blood glucose level was low; ≤70 mg/dL).
During the treatment period, clinical laboratory tests were
generally carried out at each visit. Urinary albumin/creatinine
ratio was assessed at weeks 0, 4, 8, 12, 24, 36 and 52. Bone
markers were assessed, and 12-lead electrocardiography was car-
ried out at weeks 0, 12, 24, 36 and 52. The following equation15
was used to calculate estimated glomerular ﬁltration rate (eGFR):
eGFR (mL/min/1.73 m2) = 194 9 serum creatinine-1.094 9
age-0.287 (women: 90.739).
AEs were classiﬁed according to system organ class and pre-
ferred term using MedDRA/J version 15.1 (Japanese Mainte-
nance Organization, Tokyo, Japan). Their potential relationships
with the study drug (no causal relationship or possible causal
relationship) and their severity (mild, moderate or severe) were
also assessed.
Patients were instructed to measure blood glucose levels on
≥3 days per week using a glucose meter as early in the morn-
ing as possible in the fasting state throughout the study. Data
were to be recorded in a patient diary. The patients were also
instructed to measure glucose levels, if possible, in the event of
symptoms suggestive of hypoglycemia.
Statistical Analysis
The rationale for the sample size is described in the Supporting
Information.
Efﬁcacy variables were analyzed in the full analysis set,
excluding patients without type 2 diabetes, who did not receive
the study drug or who lacked efﬁcacy data after starting the
study drug. The safety analysis set included all patients who
started the treatment period except those who did not receive
the study drug or who lacked safety data after starting treat-
ment with the study drug.
Efﬁcacy variables were analyzed descriptively for changes
over time as means – standard deviation with 95%
conﬁdence intervals, or as the number and percentage of
patients. The last observation was carried forward in the
event of missing data for the end of treatment. Safety vari-
ables were analyzed descriptively as the number and percent-
age of patients, or as means – standard deviation. No
statistical comparisons were made between the two doses of




The disposition of patients is summarized in Table 1. The most
common reasons for patient withdrawals in the treatment
phase were patient request or the occurrence of an AE. Table
S1 presents the characteristics of patients in each of the study
groups. Within each treatment regimen, the characteristics of
patients allocated to 100 or 200 mg canagliﬂozin were generally
similar. However, there were some differences among the seven
treatment regimens, especially HbA1c and duration of diabetes
(Table S1). The median compliance rate ranged from 99.44 to
100.0% among the 14 study groups.
Glycemic Control and b-Cell Function
As shown in Figure S1, HbA1c started to decrease by week 4
of treatment, reaching a plateau after approximately 12 weeks
of treatment in all study groups. The changes in HbA1c over
time were generally similar for both canagliﬂozin doses, except
in some regimens where the mean change was greater in
patients treated with 200 mg canagliﬂozin when used as
monotherapy (-0.80 and -1.00% in the 100 and 200 mg
canagliﬂozin groups, respectively) or in combination with an
a-GI (-0.91 and -1.17%) or a DPP-4 inhibitor (-1.04 and
-1.26%) (Figure 2a; Table S2). The baseline to end-point
change in HbA1c was approximately -1.0% in the other study
groups. The proportion of patients with HbA1c <7.0%
increased between weeks 24 and 52 in each of the study
groups, ranging from 31.4 to 50.7% at week 24 and from 38.8
to 59.4% at week 52 (Table S2). In a subgroup analysis, the
reduction in HbA1c was greater in patients with high baseline
values (≥8.0%) than in those with low baseline values (<8.0%;
Table S3).
FPG decreased over time in each of the study groups (Figure
S2), and decreased signiﬁcantly from baseline to the end of
treatment in each group (Figure 2b; Table S2). Canagliﬂozin
also decreased the proinsulin/C-peptide ratio, and increased
HOMA2-%B, indicating an improvement in b-cell function
(Table S2).
Other Efﬁcacy Variables
Table S2 presents the changes in other clinically relevant efﬁ-
cacy variables, including the changes in bodyweight, waist
circumference, SBP/DBP and lipid levels, from baseline to the
end of treatment.
Reductions in bodyweight were apparent within 4 weeks of
starting treatment in each of the study groups (Figure S3). The
magnitude of the bodyweight reduction between baseline and
the end of treatment was generally comparable between both
canagliﬂozin doses, although it varied among the seven treat-
ment regimens, being greater in the monotherapy group, and
in the biguanide, glinide and a-GI combination groups than in
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the sulfonylurea and thiazolidinedione combination groups
(Figure 2c; Table S2). The proportions of patients with a reduc-
tion in bodyweight of ≥5% increased between weeks 24 (range
13.7–39.5%) and 52 (range 25.4–55.3%). Reductions in waist
circumference were also observed during the study.
Reductions in SBP and DBP were observed in each of the
groups; the mean change from baseline to the end of treatment
among the study groups ranged from -2.84 to -7.78 mmHg
for SBP and from -1.90 to -4.44 mmHg for DBP (Table S2).
HDL-C and LDL-C levels increased, whereas triglyceride lev-
els and the LDL-C/HDL-C ratio decreased in each of the study
groups (Table S2).
Safety
Although AEs occurred in the majority of patients (≥72.6%),
serious AEs (SAEs) were reported in 2.6–9.2% of patients in
each of the study groups (Table S4). Five deaths occurred in
patients treated with the antihyperglycemic agents (2 patients
in the 100 mg group, 3 patients in the 200 mg group). Drug-
related AEs occurred in approximately one-third of patients in
each of the study groups (Table S4). Between 1.4 and 6.9% of
patients in each group discontinued because of AEs. The most
common study drug-related AEs included hypoglycemia/
asymptomatic hypoglycemia and pollakiuria.
The sulfonylurea dose was reduced in 5.6% (7/124) and 6.4%
(8/125) of patients in the 100 and 200 mg canagliﬂozin dose
groups, respectively. The glinide dose was reduced in 1.5% (1/
65) and 1.6% of (1/64) patients in the 100 and 200 mg dose
groups, respectively.
As expected from the properties of the combination drugs,
the incidence of hypoglycemia/asymptomatic hypoglycemia was
highest in patients treated with canagliﬂozin in combination
with a sulfonylurea (Table S4). Among patients treated with a
sulfonylurea, hypoglycemia occurred in 17.7% (22/124) and
14.4% (18/125) of patients treated with 100 or 200 mg, respec-
tively, whereas asymptomatic hypoglycemia occurred in 14.5%
(18/124) and 12.8% (16/125) of patients treated with 100 or
200 mg, respectively. There were no episodes of severe hypogly-
cemia (events that made the patient’s daily activities impossible
to perform) in any group. In patients treated with canagliﬂozin
in combination with a sulfonylurea, the incidence of hypoglyce-
mia/asymptomatic hypoglycemia (events per person-year)
decreased from 4.28 before the sulfonylurea dose reduction to
2.24 after the dose reduction in the 100 mg canagliﬂozin group
and from 8.57 to 3.09 in the 200 mg canagliﬂozin group.
Genital infections mostly occurred in females. Most of the
events were mild in severity and the patients recovered after
antifungal therapy. Urinary tract infections occurred in ≤6.5%
of patients in each group, and none of these events were severe.
Volume depletion-related AEs occurred in ≤4.8% of patients in
each of the study groups. These events were generally classiﬁed
as mild; none were severe.
Changes in laboratory values are presented in Table S5.
Reductions in liver enzymes (aspartate aminotransferase,
alanine aminotransferase and c-glutamyl transpeptidase) were
observed in each of the groups, although the magnitude of
reductions was not clearly related to the canagliﬂozin dose.
Hematocrit and blood urea nitrogen levels increased in each of
the groups, whereas the urinary albumin/creatinine ratio
decreased. Serum creatinine levels increased slightly, whereas
eGFR and serum uric acid levels decreased slightly in each of
the groups. There were no signiﬁcant changes in calcium and
phosphorus levels, whereas magnesium levels increased slightly
in all of the groups.
The mean total ketone body concentration increased in each
of the groups, although the magnitude of the increase was not
apparently related to the canagliﬂozin dose or combination
treatment. Total ketone bodies (reference range ≤130 lmol/L)
increased to ≥3,000 lmol/L in 22 patients and to ≥5,000 lmol/
L in six patients. The median total ketone body level increased
to approximately 200 lmol/L within 4–8 weeks, but then
declined to approximately 150 lmol/L in each of the groups by
week 24, and then remained stable thereafter. There was one
episode of diabetic ketoacidosis, which was rated as severe, in
one patient treated with 100 mg canagliﬂozin in combination
with a sulfonylurea. This event occurred 13 days after discon-
tinuing treatment with the study, and was accompanied by
hyperglycemia (≥600 mg/dL), subjective feeling bad and vomit-
ing. The patient’s highest total ketone body level was
13,263 lmol/L. The event was preceded by infectious gastroen-
teritis. Therefore, it was suspected that the episode of diabetic
ketoacidosis was a result of the development of fulminant type
1 diabetes mellitus after viral infection. The patient’s laboratory
data were generally consistent with the Japanese criteria for ful-
minant type 1 diabetes mellitus16. The patient’s diabetic ketoaci-
dosis resolved after treatment with insulin and was not
considered related to the study drug. This case of fulminant
type 1 diabetes mellitus was reported as a SAE.
DISCUSSION
The present study conﬁrmed that canagliﬂozin as monotherapy
or in combination with another oral antihyperglycemic agent
lowered HbA1c and FPG, with effects that were apparent
within 4–8 weeks and were sustained for 52 weeks. Further-
more, the proportion of patients with HbA1c <7.0% increased
between week 24 and week 52, showing the improvements in
HbA1c continued over 52 weeks of treatment. We also
observed marked improvements in bodyweight, BP and lipid
levels (HDL-C and triglyceride) during the study.
Some antihyperglycemic drugs, including sulfonylureas and
thiazolidinediones, are associated with weight gain17–19, espe-
cially when used in combination therapy20. Therefore, identify-
ing treatments that have beneﬁcial effects on bodyweight is
particularly important in the context of type 2 diabetes care21.
In the present study, reductions in mean bodyweight were
apparent within 4 weeks of treatment, and continued through-
out the 52-week study without an apparent rebound. Body-
weight reductions were also apparent in patients treated with a
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sulfonylurea or a thiazolidinedione, although the magnitude of
the bodyweight reduction tended to be smaller in these groups
than in the other groups. It is likely that the reductions in
bodyweight in the ﬁrst 4–8 weeks of the study are partly
related to changes in ﬂuid volume, mediated by increases in
urine volume. However, the continued reductions in body-
weight over the 52-week study suggest that changes in meta-
bolic activity also contribute to this outcome. This is supported
by the changes in lipid levels and total ketone bodies,
suggesting that the reduction in circulating glucose is compen-
sated for by increased triglyceride metabolism.
The reductions in BP and changes in lipid levels, especially
HDL-C and triglyceride levels, might be of relevance in terms
of cardiovascular disease risk, although the study was not
designed to address this possibility in terms of study duration
or sample size. The mechanism and clinical effects, if any, of
the increase in LDL-C levels observed in the present study and
in studies of other SGLT2 inhibitors22 also warrant investiga-
tion. The ongoing Canagliﬂozin Cardiovascular Assessment
Study should provide insight into the cardiovascular effects of
canagliﬂozin23.
The improvements in glycemic control and bodyweight
observed in the present study were consistent with those
reported in other clinical studies of canagliﬂozin in Western6–9
and Japanese patients10.
The progression of type 2 diabetes is invariably associated
with progressive b-cell dysfunction and loss of insulin secretion.
In the present study, we observed a reduction in the proinsu-
lin/C-peptide ratio and an increase in HOMA2-%B, similar to
the results reported by Rosenstock et al.7 and Stenl€of et al.6,
suggesting that treatment with canagliﬂozin led to some
improvement in b-cell function. Although the mechanism is
unclear, we suspect that the improvement in b-cell function
was secondary to a reduction in glucotoxicity24–26 rather than
as a direct effect of canagliﬂozin on b-cells, because b-cells do
not express SGLT2. Intriguingly, SGLT2 deletion preserved
b-cell function and increased b-cell mass in db/db mice fed a
high-fat diet for 4 weeks27, probably by preventing excess
hyperglycemia.
Study drug-related AEs occurred in approximately one-third
of patients, and the most common were pollakiuria and hypo-
glycemia/asymptomatic hypoglycemia. However, the incidences
of AEs and drug-related AEs were similar in each group, and
most were classiﬁed as mild or moderate in severity.
The incidence of hypoglycemia/asymptomatic hypoglycemia
is at least partly attributed to the combination drug, because it
was highest in patients treated with canagliﬂozin in combina-
tion with a sulfonylurea, and lowest in those treated with cana-
gliﬂozin in combination with an a-GI, which are associated
with low rates of hypoglycemia. Nevertheless, there were no
episodes of severe hypoglycemia.
Urinary tract infection and genital infection have been
reported in patients treated with canagliﬂozin, and are associ-
ated with the increased UGE28,29. However, these events were
relatively rare, were generally classiﬁed as mild in severity and
were manageable.
The rise in urinary glucose increases the osmotic pressure of
urine, hindering water reabsorption and promoting urine excre-
tion, as evidenced by the high incidence of pollakiuria. High
water loss might ultimately lead to osmotic diuresis and a
reduction in intravascular volume. However, volume depletion-
related AEs occurred in ≤4.8% of patients in each group, and
none of these events were severe. Nevertheless, slight changes
in plasma volume could explain or contribute to the increase in
hematocrit and the reduction in BP. We also noted a slight
increase in serum creatinine, which might reﬂect dehydration
over the short term.
There were increases in total ketone bodies in the early phase
of the study, which likely reﬂect the changes in metabolic activ-
ity, shifting from predominantly glucose metabolism to triglyc-
eride metabolism. However, the magnitude of the increase was
not apparently related to the canagliﬂozin dose, and the levels
gradually decreased over time. Although one patient experi-
enced diabetic ketoacidosis as a severe event, it was not consid-
ered related to the study drug. There were no apparent
explanations for the increases in ketone bodies in the other
patients.
We also observed reductions in liver enzymes, suggestive of
improvements in liver function, and in the urinary albumin/
creatinine ratio, suggestive of an improvement in kidney func-
tion.
Some limitations of the present study warrant mention,
including the descriptive nature of the analyses and the absence
of placebo or other control groups. However, the inclusion of
control groups was deemed unnecessary, because multiple stud-
ies have already conﬁrmed the superiority of canagliﬂozin to
placebo and would have exposed a large number of patients to
unnecessary harm or high withdrawal rates because of inade-
quate glycemic control. Although the inclusion of active control
groups was possible, this would have increased the complexity
of the study. Furthermore, we did not statistically compare the
doses or treatment regimens. However, our objective was to
document the long-term safety and efﬁcacy of canagliﬂozin in
combination with a variety of oral antihyperglycemic drugs in
accordance with Japanese regulatory guidelines, not to compare
its effects with those of other drugs or to compare the effects of
different doses of canagliﬂozin.
In conclusion, treatment with canagliﬂozin as monotherapy
or in combination with other oral antihyperglycemic drugs
improved glycemic control, bodyweight, BP and markers of
b-cell function in Japanese patients with type 2 diabetes. Cana-
gliﬂozin was generally well tolerated, with a low incidence of
SAEs. AEs of speciﬁc interest were generally infrequent and
were easily manageable, although the incidence of hypoglyce-
mia/asymptomatic hypoglycemia was slightly higher in patients
treated with canagliﬂozin in combination with a sulfonylurea.
The current data support the use of canagliﬂozin in clinical
practice in Japan.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Figure S1 | Change in hemoglobin A1c from baseline to each visit.
Figure S2 | Change in fasting plasma glucose from baseline to each visit.
Figure S3 | Percent change in bodyweight from baseline to each visit.
Table S1 | Baseline characteristics of patients treated with canagliﬂozin as monotherapy or in combination with other oral
antihyperglycemic drugs (full analysis set).
Table S2 | Changes in efﬁcacy variables from baseline (week 0) to the end of treatment in patients treated with canagliﬂozin as
monotherapy or in combination with other oral antihyperglycemic drugs.
Table S3 | Change in hemoglobin A1c from baseline to the end of treatment in subgroups of patients divided by hemoglobin A1c
at baseline (<8.0 vs ≥8.0%).
Table S4 | Adverse events in patients treated with canagliﬂozin as monotherapy or in combination with other oral antihyperglyce-
mic drugs.
Table S5 | Changes in laboratory parameters in patients treated with canagliﬂozin as monotherapy or in combination with other
oral antihyperglycemic drugs.
Data S1 | Rationale for the sample size.
Data S2 | References.
Data S3 | Study investigators.
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